Dr. Kelly Dooley & Dr. David Hager Named Deputy Directors for the ICTR COVID-19 Clinical Research Center
Posted by: Crystal Williams on: November 3, 2020 | Print This Page
November 3, 2020
We are very pleased to announce that Kelly Dooley, MD, MPH, PhD and David Hager, MD, PhD will join the ICTR COVID-19 Clinical Research Center as Deputy Directors.
Dr. Dooley is an Associate Professor of Medicine & Pharmacology with appointments in Clinical Pharmacology and Infectious Diseases. Her research focuses on tuberculosis therapeutics with an emphasis on clinical trials of TB drugs and HIV/TB co-treatment. She is on the scientific committees of the Tuberculosis Trials Consortium, AIDS Clinical Trials Group, and IMPAACT networks and is the Clinical Trials Site leader for JHU’s ACTG HIV trials unit. She is a consultant to WHO and has been a member of their Guidelines Development Committees for TB therapeutics She maintains an HIV clinical practice in the Bartlett Clinic. She is lead investigator for trials of therapeutics for drug-sensitive and drug-resistant TB, TB meningitis, and TB prophylaxis. Dr. Dooley is the site principal investigator for the NIH-funded ACTIV-2 network which is evaluating treatments for COVID-19 in ambulatory patients and has been critical to establishment of the ICTR COVID-19 Clinical Research Unit at Johns Hopkins Bayview Medical Center.
Dr. Hager is an Associate Professor of Medicine. He obtained his MD from Cornell University and his PHD from the JHSPH. His research interests include sepsis, intermediate care, and mechanical ventilation strategies for acute lung injury. Dr. Hager is the Medical Director of the inpatient COVID-19 ICU and serves as Associate Director for the MICU. He was the site principal investigator for the recently completed VICTAS trial of vitamin C in sepsis and is now the site principal investigator for the CDC-funded IVY Network, which studies influenza vaccine effectiveness and the epidemiology of COVID-19. In addition, he is a principal investigator or co-investigator for several ongoing and planned trials of COVID-19 therapeutics at Johns Hopkins including convalescent plasma, immunomodulators, anticoagulation, and vitamin C.
Dooley and Hager are experts in the fields of infectious diseases and critical care medicine and will apply that knowledge in their new positions. As deputy directors, they will oversee outpatient and inpatient clinical research operations and will be responsible for establishing and implementing best practices for the ICTR COVID-19 Clinical Research Center.
Please join us in welcoming our new team members.
Visit the ICTR COVID-19 Clinical Research Center Website